This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lashkari, K. Articles by Rahimi, N. Search for Related Content PubMed PubMed Citation Articles by Lashkari, K. Articles by Rahimi, N.

(American Journal of Pathology. 2000;156:1337-1344.)
© 2000 American Society for Investigative Pathology

Regular Articles

Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels Are Differentially Elevated in Patients with Advanced Retinopathy of Prematurity

Kameran Lashkari^*, Tatsuo Hirose^*, Jinoos Yazdany, J. Wallace McMeel^*, Andrius Kazlauskas^* and Nader Rahimi^§

From The Schepens Eye Research Institute,^*
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Schepens Retina Associates,
Boston, Massachusetts; the School of Medicine,
University of California Los Angeles, Los Angeles, California; and the Department of Ophthalmology,^§
School of Medicine, Boston University, Boston, Massachusetts

Although the roles of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in angiogenesis are well described, the putative roles of these factors in retinopathy of prematurity (ROP) remain unknown. We evaluated VEGF and HGF protein levels in subretinal fluid of eyes with ROP, and expression of their corresponding receptors in retrolental membranes associated with stage 5 ROP. We examined subretinal fluid samples from eyes using rhegmatogenous retinal detachment as a control. VEGF and HGF were differentially elevated in eyes with ROP. In Stage 5 ROP (n = 22), the mean VEGF and HGF levels were 14.77 ± 14.01 ng/ml and 16.56 ± 9.62 ng/ml, respectively. Interestingly, in patients with active stage 4 ROP, mean VEGF levels were highly elevated (44.16 ± 18.72 ng/ml), whereas mean HGF levels remained very low (4.77 ± 2.50 ng/ml). Next, we investigated in vivo expression of VEGF receptor-2 and HGF receptor in retrolental membranes from 16 patients with stage 5 ROP. Both VEGF receptor-2 and HGF receptor proteins were detected mainly in posterior portions of the membrane as well as in vessel walls and along the retinal interface where angiogenesis was active. These findings together suggest that VEGF and HGF play important roles in the pathogenesis of ROP.

This article has been cited by other articles:

				C Pieh, H Agostini, C Buschbeck, M Kruger, J Schulte-Monting, U Zirrgiebel, J Drevs, and W A Lagreze VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity Br. J. Ophthalmol., May 1, 2008; 92(5): 689 - 693. [Abstract] [Full Text] [PDF]

				G. Holmstrom, P. van Wijngaarden, D. J Coster, and K. A Williams Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies Br. J. Ophthalmol., December 1, 2007; 91(12): 1704 - 1708. [Abstract] [Full Text] [PDF]

				K. M. Nishiguchi, M. Nakamura, H. Kaneko, S. Kachi, and H. Terasaki The Role of VEGF and VEGFR2/Flk1 in Proliferation of Retinal Progenitor Cells in Murine Retinal Degeneration Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4315 - 4320. [Abstract] [Full Text] [PDF]

				B. Appukuttan, T. J. McFarland, M. H. Davies, L.-o. Atchaneeyasakul, Y. Zhang, B. Babra, Y. Pan, J. T. Rosenbaum, T. Acott, M. R. Powers, et al. Identification of Novel Alternatively Spliced Isoforms of RTEF-1 within Human Ocular Vascular Endothelial Cells and Murine Retina Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3775 - 3782. [Abstract] [Full Text] [PDF]

				E. S. Colombo, G. Menicucci, P. G. McGuire, and A. Das Hepatocyte Growth Factor/Scatter Factor Promotes Retinal Angiogenesis through Increased Urokinase Expression Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1793 - 1800. [Abstract] [Full Text] [PDF]

				E. W.M NG and A. P ADAMIS Anti-VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases Ann. N.Y. Acad. Sci., October 1, 2006; 1082(1): 151 - 171. [Abstract] [Full Text] [PDF]

				K. A. Rezai, D. Eliott, P. J. Ferrone, and R. W. Kim Near Confluent Laser Photocoagulation for the Treatment of Threshold Retinopathy of Prematurity Arch Ophthalmol, May 1, 2005; 123(5): 621 - 626. [Abstract] [Full Text] [PDF]

				H. Akiyama, T. Tanaka, H. Doi, H. Kanai, T. Maeno, H. Itakura, T. Iida, Y. Kimura, S. Kishi, and M. Kurabayashi Visible light exposure induces VEGF gene expression through activation of retinoic acid receptor-{alpha} in retinoblastoma Y79 cells Am J Physiol Cell Physiol, April 1, 2005; 288(4): C913 - C920. [Abstract] [Full Text] [PDF]

				Z. Duenas, J. C. Rivera, H. Quiroz-Mercado, J. Aranda, Y. Macotela, P. M. de Oca, F. Lopez-Barrera, G. Nava, J. L. Guerrero, A. Suarez, et al. Prolactin in Eyes of Patients with Retinopathy of Prematurity: Implications for Vascular Regression Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2049 - 2055. [Abstract] [Full Text] [PDF]

				R. W. I. Cooke, J. A. Drury, R. Mountford, and D. Clark Genetic Polymorphisms and Retinopathy of Prematurity Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1712 - 1715. [Abstract] [Full Text] [PDF]

				T. Usui, S. Ishida, K. Yamashiro, Y. Kaji, V. Poulaki, J. Moore, T. Moore, S. Amano, Y. Horikawa, D. Dartt, et al. VEGF164(165) as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2 Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 368 - 374. [Abstract] [Full Text] [PDF]

				R Nicoletti, I Venza, G Ceci, M Visalli, D Teti, and A Reibaldi Vitreous polyamines spermidine, putrescine, and spermine in human proliferative disorders of the retina Br. J. Ophthalmol., August 1, 2003; 87(8): 1038 - 1042. [Abstract] [Full Text] [PDF]

				A. S. Wilson, B. G. Hobbs, W.-Y. Shen, T. P. Speed, U. Schmidt, C. G. Begley, and P. E. Rakoczy Argon Laser Photocoagulation-Induced Modification of Gene Expression in the Retina Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1426 - 1434. [Abstract] [Full Text] [PDF]

				O. M. Tepper, R. D. Galiano, J. M. Capla, C. Kalka, P. J. Gagne, G. R. Jacobowitz, J. P. Levine, and G. C. Gurtner Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures Circulation, November 26, 2002; 106(22): 2781 - 2786. [Abstract] [Full Text] [PDF]

				C M Wheatley, J L Dickinson, D A Mackey, J E Craig, and M M Sale Retinopathy of prematurity: recent advances in our understanding Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2002; 87(2): F78 - 82. [Abstract] [Full Text] [PDF]

				C M Wheatley, J L Dickinson, D A Mackey, J E Craig, and M M Sale Retinopathy of prematurity: recent advances in our understanding Br. J. Ophthalmol., June 1, 2002; 86(6): 696 - 700. [Abstract] [Full Text] [PDF]

				H. Akiyama, T. Tanaka, T. Maeno, H. Kanai, Y. Kimura, S. Kishi, and M. Kurabayashi Induction of VEGF Gene Expression by Retinoic Acid through Sp1-Binding Sites in Retinoblastoma Y79 Cells Invest. Ophthalmol. Vis. Sci., May 1, 2002; 43(5): 1367 - 1374. [Abstract] [Full Text] [PDF]